Traders Buy High Volume of Call Options on Cybin (NASDAQ:HELP)

Cybin logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Investors traded 3,723 Cybin call options on Monday, about 108% above the average daily volume.
  • Cybin shares fell 11.2% to $7.88 during Monday’s trading. The company also reported a quarterly loss of $1.41 per share, missing analysts’ $0.67 loss estimate.
  • Analyst views are mixed, but the consensus rating remains Buy, with an average price target of $47.33. Insiders bought 688,000 shares worth about $8.4 million over the last quarter.
  • Five stocks we like better than Cybin.

Cybin Inc. (NASDAQ:HELP - Get Free Report) saw unusually large options trading on Monday. Investors acquired 3,723 call options on the stock. This is an increase of approximately 108% compared to the average daily volume of 1,786 call options.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. TD Cowen upped their price target on shares of Cybin from $8.00 to $62.00 and gave the company a "buy" rating in a research note on Thursday, August 20th. Wall Street Zen cut shares of Cybin from a "sell" rating to a "strong sell" rating in a report on Saturday, November 7th. Wells Fargo & Company increased their target price on Cybin from $16.00 to $22.00 and gave the stock an "overweight" rating in a research report on Thursday, October 22nd. Finally, Barclays started coverage on Cybin in a research report on Friday, September 18th. They set an "overweight" rating and a $35.00 target price on the stock. Six investment analysts have rated the stock with a Buy rating. Based on data from MarketBeat, Cybin has a consensus rating of "Buy" and an average target price of $47.33.

View Our Latest Analysis on Cybin

Cybin Stock Down 11.2%

NASDAQ:HELP traded down $0.99 during trading hours on Monday, hitting $7.88. 10,994,020 shares of the company's stock traded hands, compared to its average volume of 1,327,331. The business's fifty day simple moving average is $11.24 and its two-hundred day simple moving average is $7.81. Cybin has a 52 week low of $3.76 and a 52 week high of $15.15. The firm has a market cap of $628.82 million, a P/E ratio of -2.64 and a beta of 0.64.

Cybin (NASDAQ:HELP - Get Free Report) last issued its quarterly earnings results on Friday, November 13th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.74). On average, analysts expect that Cybin will post -2.95 EPS for the current year.

Insider Transactions at Cybin

In other Cybin news, insider Paul Glavine acquired 100,000 shares of the company's stock in a transaction on Tuesday, September 8th. The shares were acquired at an average cost of $12.47 per share, with a total value of $1,247,000.00. Following the completion of the acquisition, the insider directly owned 4,271,252 shares in the company, valued at $53,262,512.44. This trade represents a 2.40% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eric H. L. So bought 100,000 shares of the business's stock in a transaction on Tuesday, September 8th. The shares were acquired at an average price of $12.39 per share, with a total value of $1,239,000.00. Following the transaction, the insider directly owned 4,465,014 shares of the company's stock, valued at approximately $55,321,523.46. This trade represents a 2.29% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders purchased 688,000 shares of company stock worth $8,422,830. Insiders own 15.00% of the company's stock.

Institutional Trading of Cybin

A number of hedge funds have recently made changes to their positions in the stock. WealthPlan Investment Management LLC bought a new position in shares of Cybin during the 3rd quarter valued at about $1,272,000. Pale Fire Capital SE bought a new stake in Cybin in the 2nd quarter worth approximately $1,015,000. Farther Finance Advisors LLC boosted its stake in Cybin by 927.4% in the third quarter. Farther Finance Advisors LLC now owns 22,818 shares of the company's stock worth $280,000 after buying an additional 20,597 shares in the last quarter. AXQ Capital LP purchased a new stake in Cybin in the second quarter worth approximately $75,000. Finally, Blue Owl Capital Holdings LP grew its position in Cybin by 381.2% during the third quarter. Blue Owl Capital Holdings LP now owns 288,282 shares of the company's stock valued at $3,543,000 after acquiring an additional 228,371 shares during the last quarter. 17.94% of the stock is owned by institutional investors.

Cybin Company Profile

(Get Free Report)

Cybin, which changed its name to Helus Pharma, is a clinical-stage biopharmaceutical company developing psychedelic-based treatments for mental health conditions. Its research focuses on designing and evaluating investigational compounds intended to address conditions including depression and anxiety disorders. The company's pipeline has included CYB003, a deuterated psilocin analog being studied for major depressive disorder, and CYB004, an investigational DMT-based treatment studied for generalized anxiety disorder.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cybin Right Now?

Before you consider Cybin, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.

While Cybin currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines